News Article

Candesic Senior Partner Marc Kitten thoroughly enjoyed his time yesterday at Private Equity Insights in Zurich, Switzerland, alongside 500+ GPs and LPs.

Hot topics included the opportunities and challenges that will face PE in the second half of 2024, the best sectors for PE deals, how to capture investor appetite. and what LPs are really looking for.

Highlights included a panel discussion including Lauren Hasek (Partners Group), Markus Hosang (BioMedPartners), Robert Watson (Gyrus Capital), Yann Mauron, Ph.D (Pictet Group) and Thomas Zehnder (BlueOcean Ventures SA) focused on life sciences and the opportunities in Switzerland’s brightest sector.

Marc tells us: “The topic of the pharma patent cliff has become dominant in the last two years. This came out in the panel discussion, reinforced by the long-awaited revolution of digital clinical trials. There was agreement that it is difficult to predict the future of pharma but, typically, periods of disruption provide opportunities for savvy investors.”

Marc has extensive experience advising clients throughout Europe, as a specialist in health and social care, pharma, biotech, and medtech. If you are interested in contacting him, please e-mail [email protected] or send him a direct message on LinkedIn.